13F Holdings
中文EN

AMRX Amneal Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1723128 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.9%
TTM net income YoY2,159.3%
TTM EPS YoY3,900.0%
Revenue 3-yr CAGR10.2%
Net income 3-yr CAGR270.1%

Margins

Gross margin40.2%
Operating margin15.0%
Net margin4.2%
FCF margin2.8%
EBITDA margin—

Returns

ROE63.2%
ROA3.0%
ROIC (approx.)16.3%
Asset turnover0.72x

Leverage & solvency

Liabilities / assets87.8%
Debt / equity5.53x
Current ratio1.87x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.36x
Accruals ratio-1.1%
Payout ratio—
Capex / revenue2.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$3.02B$2.79B$2.39B$2.21B$2.09B
Cost of revenue$1.91B$1.77B$1.57B$1.43B$1.32B
Gross profit$1.11B$1.02B$820.57M$784.71M$768.97M
R&D expense$186.18M$190.71M$163.95M$195.69M$201.85M
SG&A expense$526.83M$476.44M$429.68M$399.70M$365.50M
Operating income$394.10M$249.33M$204.37M-$94.93M$152.72M
Pretax income$139.21M-$55.01M-$40.27M-$248.13M$31.37M
Income tax$11.28M$18.86M$8.45M$6.66M$11.20M
Net income$72.06M-$116.89M-$83.99M-$270.58M$13.16M
EBITDA$451.40M$311.93M$270.57M-$26.83M$213.42M
EPS (basic)0.23-0.38-0.48-0.860.07
EPS (diluted)0.22-0.38-0.48-0.860.07
Weighted avg. shares (diluted)324.81M308.98M176.14M150.94M151.82M
Balance sheet
Cash & equivalents$282.03M$118.42M$91.54M$35.23M$256.74M
Receivables———$741.79M$662.58M
Inventory$606.30M$612.45M$581.38M$530.74M$489.39M
Current assets$1.91B$1.59B$1.38B$1.41B$1.52B
PP&E, net$442.95M$424.91M$447.57M$469.81M$514.16M
Goodwill$595.47M$597.44M$598.63M$598.85M$593.02M
Intangibles$563.50M$732.38M$890.42M$1.10B$1.17B
Total assets$3.68B$3.50B$3.47B$3.80B$3.94B
Current liabilities$881.63M$1.13B$846.60M$752.80M$677.24M
Short-term debt$6.76M$224.21M$34.12M$29.96M$30.61M
Long-term debt$2.57B$2.16B$2.39B$2.59B$2.68B
Total debt$2.57B$2.39B$2.42B$2.62B$2.71B
Total liabilities$3.67B$3.55B$3.41B$3.59B$3.56B
Shareholders' equity-$70.79M-$109.27M$19.78M$298.42M$360.34M
Net debt$2.29B$2.27B$2.33B$2.59B$2.45B
Cash flow statement
Operating cash flow$339.99M$295.10M$345.58M$65.10M$241.82M
Capital expenditure$70.06M$51.92M$43.22M$46.41M$47.73M
Free cash flow$269.93M$243.18M$302.36M$18.69M$194.09M
Investing cash flow-$112.26M-$63.00M-$69.19M-$174.31M-$194.18M
Financing cash flow-$31.53M-$211.79M-$212.57M-$106.62M-$138.12M
Depreciation & amortization$57.30M$62.60M$66.20M$68.10M$60.70M
Stock-based compensation$31.95M$27.77M$26.82M$31.85M$28.41M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.